Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants

Canadian Journal of Cardiology

Volumn 29, Issue 7 SUPPL, 2013, Pages

  Liew, Aaron ^a   Eikelboom, John W ^a   O'Donnell, Martin ^b   Hart, Robert G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ADABI FAB; ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; FRESH FROZEN PLASMA; PLACEBO; PROTHROMBIN COMPLEX; PRT 064445; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; STOMACH LAVAGE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBIN TIME; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 84879528916     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.04.013     Document Type: Review

References (84)

1. Holbrook A., Schulman S., Witt D.M., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e152S-e184S.
2. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120:700-705.
3. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
4. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
5. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
6. Dowlatshahi D., Butcher K.S., Asdaghi N., et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012, 43:1812-1817.
7. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
8. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364:806-817.
9. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med 2012, 366:9-19.
10. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. NEngl J Med 2011, 365:699-708.
11. Mega J.L., Braunwald E., Murphy S.A., et al. Rivaroxaban in patients stabilized after a ST-elevation myocardial infarction: results from the ATLAS ACS 2-TIMI 51 trial. JAm Coll Cardiol 2013, 61:1853-1859.
12. Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
13. Eriksson B.I., Dahl O.E., Huo M.H., et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105:721-729.
14. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. NEngl J Med 2008, 358:2765-2775.
15. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
16. Lassen M.R., Gallus A., Raskob G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. NEngl J Med 2010, 363:2487-2498.
17. Ginsberg J.S., Davidson B.L., Comp P.C., et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. JArthroplasty 2009, 24:1-9.
18. Eriksson B.I., Dahl O.E., Rosencher N., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. JThromb Haemost 2007, 5:2178-2185.
19. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. NEngl J Med 2008, 358:2776-2786.
20. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
21. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. NEngl J Med 2009, 361:594-604.
22. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
23. Goldhaber S.Z., Leizorovicz A., Kakkar A.K., et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. NEngl J Med 2011, 365:2167-2177.
24. Cohen A.T., Spiro T.E., Buller H.R., et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. NEngl J Med 2013, 368:513-523.
25. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEngl J Med 2009, 361:2342-2352.
26. Schulman S., Kakkar A., Schellong S., et al. ARandomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). Proc ASH 2011, abstract 205.
27. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. NEngl J Med 2013, 368:709-718.
28. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. NEngl J Med 2010, 363:2499-2510.
29. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. NEngl J Med 2013, 368:699-708.
30. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. NEngl J Med 2012, 366:1287-1297.
31. Hart R.G., Diener H.C., Yang S., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43:1511-1517.
32. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e44S-e88S.
33. Holbrook A.M., Pereira J.A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
34. Witt D.M., Delate T., Clark N.P., et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. JThromb Haemost 2010, 8:744-749.
35. Zubkov A.Y., Mandrekar J.N., Claassen D.O., et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol 2008, 65:1320-1325.
36. Witt D.M., Delate T., Clark N.P., et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009, 114:952-956.
37. Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120:897-902.
38. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., et al. Amethod to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
39. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
40. Van Spall H.G., Wallentin L., Yusuf S., et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012, 126:2309-2316.
41. De Caterina R., Husted S., Wallentin L., et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013, 109:569-579.
42. Whitlock R.P., Sun J.C., Fremes S.E., Rubens F.D., Teoh K.H. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e576S-e600S.
43. Vahanian A., Alfieri O., Andreotti F., et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012, 42:S1-S44.
44. Pare G., Eriksson N., Lehr T., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013, 127:1404-1412.
45. Xarelto (rivaroxaban). Product information. Bayer AG, Leverkusen, Germany. Available at: Accessed May 22, 2013. http://www.bayer.ca/files/Xarelto%20English%2012APR2013.pdf?
46. Eliquis (apixaban). Product information. Bristol-Myers Squibb Co, Princeton, NJ. Available at: Accessed May 22, 2013. http://www.pfizer.ca/en/our_products/products/monograph/313.
47. PRADAXA (dabigatran etexilate mesylate). Product information. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT. Available at: Accessed May 22, 2013. http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/Pradax-pm.pdf.
48. Douketis J.D. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 2010, 16:3436-3441.
49. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
50. Stangier J., Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012, 23:138-143.
51. Barrett Y.C., Wang Z., Frost C., Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104:1263-1271.
52. Mani H., Rohde G., Stratmann G., et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012, 108:191-198.
53. Samama M.M., Contant G., Spiro T.E., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012, 107:379-387.
54. Gomes T., Mamdani M.M., Holbrook A.M., et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013, 185:E121-E127.
55. Weitz J.I., Quinlan D.J., Eikelboom J.W. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012, 126:2428-2432.
56. Dezee K.J., Shimeall W.T., Douglas K.M., Shumway N.M., O'Malley P.G. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006, 166:391-397.
57. Hanger H.C., Geddes J.A., Wilkinson T.J., Lee M., Baker A.E. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J 2013, 43:308-316.
58. Huttner H.B., Schellinger P.D., Hartmann M., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37:1465-1470.
59. Woo C.H., Patel N., Conell C., et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg 2012, [Epub ahead of print].
60. Schiele F., van Ryn J., Canada K., et al. Aspecific antidote for dabigatran: functional and structural characterization. Blood 2013, 121:3554-3562.
61. Lu G., Deguzman F.R., Hollenbach S.J., et al. Aspecific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19:446-451.
62. Perzborn E., Trabandt A., Selbach K., Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. Pathophysiol Haemost Thromb 2010, 37:OC251.
63. Zhou W., Zorn M., Nawroth P., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013, 44:771-778.
64. Godier A., Miclot A., Le Bonniec B., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012, 116:94-102.
65. Olesen J.B., Christiansen K., Ingerslev J., Sørensen B., Hvas A. Haemostatic response to invitro addition of recombinant factor VIla, prothrombin complex concentrate, or concentrate of factor IX/X in blood spiked with a direct Xa inhibitor. JThromb Haemost 2009, 7(suppl 2):448.
66. Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Paper presented at: 50th Annual Meeting and Exposition of the American Society of Hematology. December 5-9, 2008; San Francisco, CA.
67. van Ryn J., Schurer J., Kink-Eiband M., Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with exvivo markers of anticoagulation. Blood 2011, 118. abstract 2316.
68. Pragst I., Dörr B., Kaspereit F., et al. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. Pathophysiol Haemost Thromb 2010, 37:A94.
69. van Ryn J., Ruehl D., Priepke H., Hauel N., Wienen W. Reversibility of the anticoagulation effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008, 93(suppl 1). 148 abstract 0370.
70. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
71. Escolar G, Arellano-Rodrigo E, Carles Reverter J, et al. Coagulation factor concentrates restore alterations in hemostasis induced by a high dose of apixaban: studies invitro with circulating human blood. Paper presented at: 54th Annual Meeting of the American Society of Hematology. December 8-11, 2012; Atlanta, GA.
72. Marlu R., Hodaj E., Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover exvivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
73. Tinel H., Huetter J., Perzborn E. Recombinant factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban - a novel, oral, direct factor Xa inhibitor-in rats. JThromb Haemost 2007, 5(suppl 2). abstract P-W-652.
74. Dumkow L.E., Voss J.R., Peters M., Jennings D.L. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 2012, 69:1646-1650.
75. van Ryn J., Sieger P., Kink-Eiband M., Gansser D., Clemens A. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal invitro. Blood 2009, 114:22.
76. Woo J.S., Kapadia N., Phanco S.E., Lynch C.A. Positive outcome after intentional overdose of dabigatran. JMed Toxicol 2013, 9:192-195.
77. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
78. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013, 109:596-605.
79. Van Ryn J., Neubauer M., Flieg R., et al. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an invitro test system [abstract 0700]. Haematologica 2010, 95(suppl 2):293.
80. Rybinnik I., Mullen M.T., Messe S., Kasner S.E., Cucchiara B. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. JStroke Cerebrovasc Dis 2013, [Epub ahead of print].
81. Akwaa F., Spyropoulos A.C. Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. Curr Treat Options Cardiovasc Med 2013, 15:288-298.
82. Siegal D.M., Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. JThromb Thrombolysis 2013, 35:391-398.
83. Donadini M.P., Ageno W., Douketis J.D. Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach. Drugs 2012, 72:1965-1975.
84. Kaatz S., Kouides P.A., Garcia D.A., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87(suppl 1):S141-S145.